drugset / Trial / NCT05894148
Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults
Phase 1
Completed
24 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Affiliated Hospital of North Sichuan Medical College · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
To evaluate the safety and tolerability of multiple-dose subcutaneous injections of Genakumab for Injection in Chinese healthy adult volunteers.
Timeline
- Start
- 2023-03-06
- Primary completion
- 2023-11-30
- Completion
- 2023-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Genakumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 200 mg | Subcutaneous |